Pressmeddelande

BioStock: Elicera’s CEO: ” iTANK has great potential in treating solid tumours”

Cision Publicerad: 16 Nov 2023 13:23

Elicera’s Q3 report was filled with updates from the ongoing cell therapy projects, where they see potential value-driving milestones in the near future. BioStock talked to Elicera’s CEO and co-founder Jamal El-Mosleh, who shares his view about the short-term goals, but also about the overarching long-term goal – to out-license the company’s platform technology iTANK to CAR T-developing pharmaceutical companies worldwide.

Read the full interview with Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2023/11/eliceras-ceo-itank-has-great-potential-in-treating-solid-tumours/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Nyheter om Elicera Therapeutics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!